Design of the Prostate Cancer Prevention Trial (PCPT).

@article{Feigl1995DesignOT,
  title={Design of the Prostate Cancer Prevention Trial (PCPT).},
  author={Polly Feigl and Brent A. Blumenstein and I L Thompson and John C Crowley and Marco Wolf and Barnett S. Kramer and Charles Arthur Coltman and Otis W Brawley and Leslie G. Ford},
  journal={Controlled clinical trials},
  year={1995},
  volume={16 3},
  pages={150-63}
}
The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsy-proven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) and half will receive placebo (one matching tablet per day) for 7 years. The trial is designed to have 92% power to detect a 25% reduction in period prevalence of biopsy-proven disease using a two-sided test with alpha = 0.05. The trial is… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
32 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…